Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Subscribe To Our Newsletter & Stay Updated
